DRIVING GROWTH THROUGH ADHESIVE SYSTEMS, INNOVATION, AND DIGITAL MARKET LEADERSHIP

Today, Sika is hosting an investor day at its largest adhesive factory, located in Duedingen, Switzerland. The day features presentations from Sika’s management team, outlining key group-wide initiatives for growth, with a focus on adhesives. The event will provide updates on Sika’s Fast Forward program, the acquisition of Akkim, and Sika’s innovation and go-to-market strategies. CEO Thomas Hasler will address Sika’s commitment to delivering strong and sustainable growth, driven by targeted investments in growth segments and innovation.

Thomas Hasler, Chief Executive Officer: “Adhesives and sealants represent a key competitive strength for Sika and offer attractive opportunities for further growth. We are ideally positioned to gain additional market share in this sector. Moreover, the acquisition of Akkim has created a highly scalable platform that allows us to further accelerate our growth trajectory and double Akkim’s sales within five years. At the same time, our strong innovation pipeline enables us to deliver sustainable, high-performance solutions that create significant value for our customers.”

At the Investor Day, Sika is providing a deep dive into one of its five core technologies: Adhesive Systems. This technology is used across most of Sika’s eight Target Markets. Adhesive technologies continue to be a major growth driver in both the construction industry and across wider industrial applications.

Members of Group Management are also providing an in-depth update on the Fast Forward program, Sika’s digital transformation plans and how these are designed to accelerate Sika’s profitable market share growth across the industry. Fast Forward remains on track to deliver CHF 80 million in benefits in 2026 and will drive a profit uplift of CHF 150 to CHF 200 million through to 2028. Today’s event includes updates on the progress made to date and provides insights on the innovation, channel penetration, and go-to-market strategies that are driving Fast Forward’s achievements.

An exclusive tour of Sika’s Duedingen manufacturing site offers an inside look at the production of high-performance adhesives and sealants, showcasing advanced manufacturing technologies, operational excellence, and commitment to innovation.

SIKA CORPORATE PROFILE
Sika is a specialty chemicals company with a globally leading position in the development and production of systems and products for bonding, sealing, damping, reinforcing, and protection in the building sector and industry. Sika has subsidiaries in 103 countries around the world, produces in over 400 factories, and develops innovative technologies for customers worldwide. In doing so, it plays a crucial role in enabling the transformation of the construction and transportation industries toward greater environmental compatibility. In 2025, Sika’s 33,700 employees generated annual sales of CHF 11.20 billion.

CONTACT
Dominik Slappnig
Corporate Communications and
Investor Relations
+41 58 436 68 21
slappnig.dominik@ch.sika.com

The media release can be downloaded from the following link:
Media Release

  • Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1
  • By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes1
  • The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026

Basel, 1 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine (NEJM). The evERA trial is evaluating giredestrant, an investigational oral selective oestrogen receptor degrader (SERD), in combination with everolimus in people with oestrogen receptor (ER)-positive locally advanced or metastatic breast cancer who had disease progression or recurrence following treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy.1

“Despite advancements with CDK4/6 inhibitor treatment in the first-line setting, many people with advanced breast cancer will eventually experience disease progression as their tumours become resistant to endocrine therapy,” said Dr Erica L. Mayer, Medical Oncologist at Dana-Farber Cancer Institute. “The evERA trial demonstrated that the giredestrant combination significantly delayed disease progression, potentially offering a promising all-oral treatment option in a setting where there remains a need for additional treatments to improve patient outcomes.”

In the ESR1-mutated population, the median PFS was 10.0 months with giredestrant plus everolimus compared with 5.5 months in the comparator arm (stratified hazard ratio [HR]=0.38, 95% CI: 0.27-0.54, p<0.001).1 In the intent-to-treat (ITT) population, the median PFS was 8.8 months compared with 5.5 months in the giredestrant and comparator arms, respectively (HR=0.56, 95% CI: 0.44-0.71, p<0.001).1 Overall survival (OS) data were immature at the time of analysis, but a clear positive trend has been observed in the ITT (HR=0.69, 95% CI: 0.47-1.00) and ESR1-mutated populations (HR=0.62, 95% CI: 0.38-1.02).1 Follow-up for OS will continue to the next analysis. Adverse events for the giredestrant combination were manageable and consistent with the known safety profiles of the individual medicines.1 No unexpected safety findings were observed, including no photopsia and low rates of bradycardia.1

“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the positive phase III lidERA results in early breast cancer, these findings reinforce the potential of giredestrant to redefine care in both metastatic and early disease settings.”

Additional evERA analyses were presented at the 2026 American Society of Clinical Oncology Annual Meeting, showing that giredestrant plus everolimus prolongs PFS2 (time from randomisation to disease progression following second-line therapy) and chemotherapy-free survival compared with standard endocrine therapy, suggesting that the clinical benefit may be sustained beyond initial progression.2

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of breast cancer cases.3 Resistance to endocrine therapies, particularly in the post-CDK inhibitor setting, increases the risk of disease progression and is associated with poor outcomes.3,4

evERA was the first positive phase III readout for giredestrant, followed by the lidERA Breast Cancer study in the early-stage setting.1,5 Based on these evERA data, the US Food and Drug Administration (FDA) accepted Roche’s New Drug Application (NDA) for giredestrant in combination with everolimus for the treatment of people with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after completing endocrine-based adjuvant therapy, or who have progressed on at least one endocrine-based regimen in the metastatic setting. The FDA is expected to decide on the application by 18 December 2026. The FDA also accepted an NDA under Priority Review for giredestrant as an adjuvant treatment for adults with ER-positive, HER2-negative, stage I, II, and III breast cancer based on the lidERA results. The FDA has set a Prescription Drug User Fee Act goal date of 30 November 2026.

Roche’s expanding giredestrant clinical development programme spans distinct treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people with HR-positive breast cancer as possible.

About the evERA Breast Cancer study
evERA Breast Cancer [NCT05306340] is a phase III, randomised, open-label, multicentre study evaluating the efficacy and safety of giredestrant in combination with everolimus versus standard endocrine therapy in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy, either in the adjuvant or locally advanced/metastatic setting.6

The co-primary endpoints are investigator-assessed progression-free survival in the intention-to-treat and ESR1-mutated populations, defined as the time from randomisation to the time when the disease progresses or a patient dies from any cause.6 In the post-CDK inhibitor setting, up to 40% of people with ER-positive disease have ESR1 mutations.7,8 Key secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate and safety.6

About giredestrant
Giredestrant is an investigational, oral, potent next-generation selective oestrogen receptor degrader and full antagonist.9

Giredestrant is designed to block oestrogen from binding to the oestrogen receptor (ER), triggering its breakdown (known as degradation) and stopping or slowing down the growth of cancer cells.10

Giredestrant has an extensive clinical development programme including five company-sponsored phase III clinical trials to address the needs of patients acrossmultiple treatment settings and lines of therapy:

  • Giredestrant versus standard endocrine therapy as adjuvant treatment in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (lidERA Breast Cancer; NCT04961996)11
  • Giredestrant plus everolimus versus standard endocrine therapy plus everolimus in ER-positive, HER2-negative, locally advanced or metastatic breast cancer (evERA Breast Cancer; NCT05306340)6
  • Giredestrant plus palbociclib versus letrozole plus palbociclib in ER-positive, HER2-negative, endocrine-sensitive, recurrent locally advanced or metastatic breast cancer (persevERA Breast Cancer; NCT04546009)12
  • Giredestrant plus investigator’s choice of a cyclin-dependent kinase (CDK)4/6 inhibitor versus fulvestrant plus a CDK4/6 inhibitor in ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy (pionERA Breast Cancer; NCT06065748)13
  • Giredestrant plus Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous) versus Phesgo in ER-positive, HER2-positive locally advanced or metastatic breast cancer (heredERA Breast Cancer; NCT05296798)14

About hormone receptor (HR)-positive breast cancer
Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year.15 Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type.16

HR-positive, human epidermal growth factor receptor 2-negative breast cancer accounts for approximately 70% of breast cancer cases and the majority are diagnosed in the early-stage.3 A defining feature of HR-positive breast cancer is that its tumour cells have receptors that attach to hormones like oestrogen, which can contribute to tumour growth.17

Despite treatment advances, HR-positive breast cancer remains particularly challenging to treat due to its biological complexity.18 Patients often face the risk of disease progression, treatment side effects and resistance to endocrine therapy.18,19 There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people’s lives.18,19

About Roche in breast cancer
Roche has been advancing breast cancer research for more than 30 years, and it continues to be a major focus of research and development. Our legacy began with the development of the first targeted therapy for human epidermal growth factor receptor 2-positive breast cancer, and we continue to push the boundaries of science to address the complexities of all breast cancer subtypes.

By leveraging our dual expertise in pharmaceuticals and diagnostics, we are dedicated to providing tailored treatment approaches and improving outcomes for every patient, from early to advanced stages of the disease. Together with our partners, we are relentlessly pursuing a cure, as we strive for a future where no one dies from breast cancer.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Mayer E, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. NEJM; 2026 October. DOI:10.1056/NEJMoa2602457.
[2] Jhaveri K, et al. Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29 – June 02; Chicago, Illinois, US. #1016.
[3] Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696.
[4] Sahin T, et al. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Treatment Reviews. 2025 April;135:102924.
[5] Bardia A, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Presented at: San Antonio Breast Cancer Symposium (SABCS); 2025 December 9-12; San Antonio, Texas, United States. #GS1-10.
[6] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician’s Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT05306340.
[7] Meisel J L, et al. Real-world estrogen receptor 1 (ESR1) testing patterns and results in U.S. patients with metastatic breast cancer, 2018-2024. JCO Oncol Pract. 2025;21:579.
[8] Chaudhary N, et al. CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. npj Breast Cancer. 2024;10,15.
[9] Martin M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Presented at: The ESMO Annual Meeting; 2022 September 9-13; Paris, France. Abstract #211MO.
[10] Metcalfe C, et al. GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. Presented at: SABCS; 2018 December 4-8; San Antonio, Texas, USA. Abstract #P5-04-07.
[11] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT04961996.
[12] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT04546009.
[13] ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT06065748.
[14] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT05296798.
[15] World Health Organization. Breast Cancer [Internet; cited 2026 September]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
[16] World Health Organization. Cancer Today [Internet; cited 2026 September]. Available from: https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&types=1&group_populations=1&sexes=2&key=asr&age_end=14.
[17] National Cancer Institute. Hormone Therapy for Breast Cancer [Internet; cited 2026 September]. Available from: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet.
[18] Hanker A, et al. Overcoming Endocrine Resistance in Breast Cancer. Canc Cell. 2020 Apr 13;37(4):496–513.
[19] Başaran G, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018 Feb;63:144-55.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan 
Phone: +41 79 377 83 75
Albert Thottiyil 
Phone: +41 79 775 66 12

Attachment

Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

  • REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron
  • Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits
  • Sanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET

Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies’ more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world.

“This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world’s leading immunology businesses,” said Belén Garijo, Chief Executive Officer of Sanofi. “By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.”

Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). IL-13 antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis, and the other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have the option to include in the collaboration Sanofi’s lunsekimig, an investigational bispecific Nanobody® VHH therapy targeting TSLP and IL-13, exercisable upon completion of its phase 3 studies for chronic obstructive pulmonary disease.

“The Regeneron-Sanofi Alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster,” said Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer of Regeneron. “By expanding our Alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.”

Under the terms of the agreement, Regeneron will receive an upfront payment of $1 billion from Sanofi, with the potential for development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercialization costs for the new programs and will split future profits from these potential products 50:50 on a global basis. Regeneron will lead research and development activities, and Sanofi will lead global commercial efforts. The existing profit-sharing agreement regarding Dupixent will not change.

“The companies’ clinical and commercial Alliance dates to 2003 and has resulted in multiple approved medicines to date, including Dupixent, which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease, with over 1.5 million active patients worldwide,” said George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.”

The companies have settled their prior collaboration-related litigation.

Conference call for investors and analysts
Sanofi and Regeneron will host a conference call for investors and analysts today at 14:00 CET/8:00am ET. A presentation will be available for download from the Investor Relations section of sanofi.com and regeneron.com when the conference call starts.

Participants may access the conference call via webcast on the ‘Upcoming Events’ page of Sanofi’s website at https://www.sanofi.com/en/investors/news-events/upcoming-events, tab ‘Presentations’ and on the ‘Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com/events-and-presentations. To participate via telephone, please register in advance at this link.

About Dupixent
Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
 
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
 
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi 
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Sanofi Media Relations

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Laura Romby | +33 6 74 16 74 29 | laura.romby@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com

Sanofi Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com

Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Regeneron Media Relations
Christina Chan | +1 914-383-6374 | christina.chan@regeneron.com 
Alexandra Bowie | +1 914-346-0588 | alexandra.bowie@regeneron.com 

Regeneron Investor Relations
Ryan Crowe | +1 914-847-8790 | ryan.crowe@regeneron.com
Mark Hudson | +1 914-847-3482 | mark.hudson@regeneron.com

Sanofi forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these, and similar expressions are intended to identify forward-looking statements.
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation; trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markest Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation the research and clinical programs discussed or referenced in this press release such as those evaluating Regeneron-discovered antibodies targeting interleukin-13 (IL-13), interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα) as well as a bispecific antibody targeting IL-4xIL-13; the potential for any license, collaboration, or supply agreement, including Regeneron’s amended license and collaboration agreement with Sanofi discussed in this press release, to be cancelled or terminated without realizing the expected benefits of such agreement; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including based on the amended license and collaboration agreement discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as those referenced above; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Attachment

  • 37,408 vehicles were delivered in September 2026, increasing by 7.7% year-over-year
  • 109,178 vehicles were delivered in the three months ended September 2026, increasing by 25.4% year-over-year
  • 300,301 vehicles were delivered in the first three quarters of 2026, increasing by 49.2% year-over-year
  • Cumulative deliveries reached 1,297,893 as of September 30, 2026

SHANGHAI, China, Oct. 01, 2026 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its September and third quarter 2026 delivery results.

The Company delivered 37,408 vehicles in September 2026, representing an increase of 7.7% year-over-year. The deliveries consisted of 21,318 vehicles from NIO brand, 8,763 vehicles from ONVO brand, and 7,327 vehicles from FIREFLY brand. The Company delivered 109,178 vehicles in the third quarter of 2026, representing an increase of 25.4% year-over-year. The Company delivered 300,301 vehicles in the first three quarters of 2026, representing an increase of 49.2% year-over-year. Cumulative deliveries reached 1,297,893 as of September 30, 2026.

On September 20, 2026, the first anniversary of its launch, the NIO All-New ES8 reached its 150,000th delivery milestone, ranking first in cumulative sales among large SUVs and vehicles priced above RMB400,000 during the first year. On September 23, 2026, the NIO ES9 reached its 30,000th delivery milestone since deliveries began on May 28, 2026, ranking first in monthly sales among battery electric vehicles priced above RMB500,000 for three consecutive months. The strong performance of the All-New ES8 and ES9 further strengthens NIO’s position in the premium electric SUV market, supported by its flagship products, full-cycle service offerings and charging and battery-swapping infrastructure.

About NIO Inc.
NIO Inc. is a pioneer and a leading company in the global smart electric vehicle market. Founded in November 2014, NIO aspires to shape a sustainable and brighter future with the mission of “Blue Sky Coming”. NIO envisions itself as a user enterprise where innovative technology meets experience excellence. NIO designs, develops, manufactures and sells smart electric vehicles, driving innovations in next-generation core technologies. NIO distinguishes itself through continuous technological breakthroughs and innovations, exceptional products and services, and a community for shared growth. NIO provides premium smart electric vehicles under the NIO brand, premium smart electric vehicles for families through the ONVO brand, and high-end smart electric compact cars with the FIREFLY brand.

Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. NIO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements, circulars or other publications made on the websites of each of The Stock Exchange of Hong Kong Limited (the “SEHK”) and the Singapore Exchange Securities Trading Limited (the “SGX-ST”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIO’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIO’s strategies; NIO’s future business development, financial condition and results of operations; NIO’s ability to develop and manufacture vehicles of sufficient quality and appeal to customers on schedule and on a large scale; its ability to ensure and expand manufacturing capacities including establishing and maintaining partnerships with third parties; its ability to provide convenient and comprehensive power solutions to its customers; the viability, growth potential and prospects of the battery swapping, BaaS, and NIO Assisted and Intelligent Driving and its subscription services; its ability to improve the technologies or develop alternative technologies in meeting evolving market demand and industry development; NIO’s ability to satisfy the mandated safety standards relating to motor vehicles; its ability to secure supply of raw materials or other components used in its vehicles; its ability to secure sufficient reservations and sales of its vehicles; its ability to control costs associated with its operations; its ability to build its current and future brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIO’s filings with the SEC and the announcements and filings on the websites of each of the SEHK and SGX-ST. All information provided in this press release is as of the date of this press release, and NIO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please visit: http://ir.nio.com

Investor Relations
ir@nio.com

Media Relations
global.press@nio.com

BEIJING, China, Oct. 01, 2026 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 31,817 vehicles in September 2026. As of September 30, 2026, Li Auto’s cumulative deliveries reached 1,833,651.

In September, Li Auto delivered over 10,000 units of the new Li L6 and expanded its BEV lineup with the launches of the new Li MEGA Home and Li i9 Home. The Company also rolled out MACH VLA 2.0 via an OTA update to nearly one million Li AD Max vehicles powered by the Orin-X and Thor chips. In October, Li Auto will launch the new Li i6 and will also make its debut in Europe at the Paris Motor Show, where it will introduce Li i6 to the European market.

As of September 30, 2026, the Company had 485 retail stores in 160 cities, 532 servicing centers and Li Auto-authorized servicing shops operating in 217 cities. The Company also had 4,188 super charging stations in operation equipped with 23,077 charging stalls in China.

About Li Auto Inc.

Li Auto Inc. is a leader in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Be Proactive, Change the World. Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer in successfully commercializing extended-range electric vehicles in China. While firmly advancing along this technological route, it builds platforms for battery electric vehicles in parallel. The Company leverages technology to create value for users. It concentrates its in-house development efforts on proprietary range extension systems, innovative electric vehicle technologies, and smart vehicle solutions. The Company started volume production in November 2019. It offers high-tech flagship family MPVs, Li L series extended-range electric SUVs, and Li i series battery electric SUVs. The Company will continue to expand its product lineup to target a broader user base.

For more information, please visit: https://ir.lixiang.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “targets,” “likely to,” “challenges,” and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) and The Stock Exchange of Hong Kong Limited (the “HKEX”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto’s strategies, future business development, and financial condition and results of operations; Li Auto’s limited operating history; risks associated with extended-range electric vehicles and high-power charging battery electric vehicles; Li Auto’s ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto’s ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto’s ability to compete successfully; Li Auto’s ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto’s vehicles; Li Auto’s ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto’s filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Li Auto Inc.
Investor Relations
Email: ir@lixiang.com

Christensen Advisory
Tel: +86-10-5900-1548
Email: Li@christensencomms.com

ABU DHABI, United Arab Emirates, Sept. 30, 2026 (GLOBE NEWSWIRE) — FREELANDER, jointly developed by JLR and Chery, held its Global Brand Launch at the iconic Emirates Palace Mandarin Oriental in Abu Dhabi on 29 September under the theme Beyond the Legend. The brand presented the international left-hand drive (LHD) variant of FREELANDER 8 to government officials, industry partners and media.

Distinguished guests join the official group photo at the FREELANDER Global Brand Launch

Distinguished guests join the official group photo at the FREELANDER Global Brand Launch

The event was attended by eight dignitaries holding the title of His Excellency, including H.E. Hamad Sayah Al Mazrouei, Undersecretary of the Abu Dhabi Department of Economic Development. Mohamed Ali Al Kamali, Chief Trade and Industry Officer at the Abu Dhabi Investment Office, also attended. They were joined by Charlie Zhang, Executive Vice President of Chery International; Tim Zhang, General Manager of Chery International’s Middle East Region; and Lucia Mao, CEO of FREELANDER International.

First introduced in 1997, Freelander has evolved from a single nameplate into a standalone global brand. Its positioning as a British Premium Intelligent All-Terrain Brand combines British design heritage with advanced technology. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub that leads its design. Chery provides advanced intelligent technology and a top-tier global supply chain.

Lucia Mao, CEO of FREELANDER International, said, “FREELANDER is a British legend. But we want to do more than just bring it back. Chinese technology opens up new possibilities. That is what ‘Beyond the Legend’ means. British soul. Chinese intelligence. A legend going further than ever.”

Image 2 Lucia Mao delivers the keynote speech on stage

Lucia Mao delivers the keynote speech on stage

FREELANDER 8 combines a Castle-Style Body and Signature Interlocking Headlights with premium materials and an intelligent cabin powered by the Qualcomm SA8295P chip. L2+ driver assistance comes as standard, with more than 30 assistance functions; Super Intelligent Valet Parking (SIVP) will be available in selected markets for supported parking scenarios, subject to the system’s operating conditions and the driver’s responsibilities. For the Middle East’s high temperatures, a 45 cc air-conditioning compressor delivers rapid cooling. In an internal stationary test after two hours in the sun, air temperature at the driver’s head position fell by around 33 degrees Celsius within ten minutes. The Middle East-exclusive Qibla Compass shows the direction of Makkah, prayer times, distance to the Kaaba and the Hijri calendar.

The i-ATS (Intelligent All-Terrain System) offers nine modes: seven terrain programmes, including Sand Mode, plus Smart Mode and Expert Mode. Working with the electrified powertrain and chassis, it supports confident driving across changing surfaces. FREELANDER 8 can pass an 800 mm cross-axle test, climb a 70% grade and wade through water up to 900 mm deep.

The launch also highlighted the engineering behind FREELANDER 8. Its electrified powertrain combines a 2.0T dedicated hybrid engine with a 34.12 kWh LFP battery and dual-motor all-wheel drive, delivering up to 460 kW of peak power and 662 N·m of peak torque. FREELANDER 8 delivers a total range of 886 km with a full tank and a fully charged battery, and an all-electric range of 110 km, both on the combined cycle. The chassis pairs a dual-chamber air suspension with Continuously Controlled Damping (CCD), offering a maximum ground clearance of 266 mm. Specifications vary by market and trim level. Figures stated apply to the Middle East market model only.

Image 3 H.E. Hamad Sayah Al Mazrouei, Undersecretary of ADDED, experiences FREELANDER 8 at the FREELANDER Global Brand Launch

H.E. Hamad Sayah Al Mazrouei, Undersecretary of ADDED, experiences FREELANDER 8 at the FREELANDER Global Brand Launch

“Before you face extreme heat, heavy rain or rough ground, we put the car through it first. So wherever you go, you can drive with confidence,” said Peter Matkin, Chief Engineer at Chery International R&D Centre. More than 1,000 test vehicles support global validation, including over 200 dedicated to all-terrain durability testing, covering 2.15 million kilometres in those tests.

The Middle East serves as the strategic starting point for FREELANDER’s international roll-out. In the UAE, the brand has established dealer partnerships with Al Tayer Motors for Dubai and the Northern Emirates, and Premier Motors for Abu Dhabi, forming the foundation of its local sales and service network. Customers in the UAE can now register their interest in FREELANDER 8. The broader international roll-out will proceed in stages, beginning with LHD markets before expanding to right-hand drive (RHD) and EU specification markets.

Further details on safety, interior space, service and other product information will be announced at the product launch through FREELANDER’s official channels and local market communications.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub that leads its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand is supported by a strong global foundation, including more than 5,000 employees, five strategic hubs, and fully integrated capabilities spanning design, R&D, manufacturing, and global operations.

Vincent CHEN
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/2153801d-f959-445f-bb1e-fa96c3ece9d6

https://www.globenewswire.com/NewsRoom/AttachmentNg/e04cd3f3-39ed-4d78-b77f-a3c7ae7f4a9c

https://www.globenewswire.com/NewsRoom/AttachmentNg/33cc252a-e22c-406a-a257-9c95b5d8939c

Sulista South discovery spans 500 m of strike, as new strike extensions and successful infill drilling at Sulista East advance towards year-end Mineral Resource Estimate update

SYDNEY, Sept. 30, 2026 (GLOBE NEWSWIRE) — Brazilian Rare Earths Limited (ASX: BRE / OTCQX: BRELY) (‘BRE’) announces results from its Stage 1 exploration drilling and prospecting at Sulista South and ongoing infill and step-out drilling at the Sulista East Deposit, approximately 80 km southwest of Monte Alto, in Bahia, Brazil.

HIGHLIGHTS

  • New high-grade discovery at Sulista South: Stage 1 diamond drilling 800 m south of Sulista East deposit has intersected multiple stacked rare earth mineralised seams across 500 m of strike. Mineralisation reaches up to 18 m true thickness, with reported grades up to 13.3% TREO. Mineralisation remains open along strike and at depth.
  • More than 4.5 km of exploration corridor remains untested: The southern exploration corridor beyond the new discovery offers substantial scope for further exploration, with a diamond drilling campaign exceeding 10,000 m underway.
  • Sulista East strike extended 430 m with step-outs: Diamond drilling has extended the Sulista East strike by 350 m north and 80 m south beyond the current Mineral Resource footprint, supporting assessment of potential resource additions.
  • Infill drilling builds geological confidence: Successful infill drilling at Sulista East has enhanced the continuity and geological confidence of the main mineralised deposit, which will inform assessment of potential conversions from Inferred to Indicated classification.

SULISTA SOUTH DISCOVERY AND SULISTA EAST EXPANSION

FIGURE 1: SULISTA SOUTH DISCOVERY AND SULISTA EAST EXPANSION

RESOURCE UPDATE AND DEVELOPMENT PATHWAY

  • Infill drilling validates Sulista East: Close-spaced drilling at Sulista East has confirmed continuity, geometry and grade distribution across areas currently classified as Inferred, strengthening confidence in the geological model and supporting potential conversion from Inferred to Indicated classification.
  • Sulista offers potential growth beyond the published Scoping Study case: Sulista was excluded from the Monte Alto + Camaçari Scoping Study. Sulista has the potential to provide additional high-grade feed to the planned Camaçari processing hub, subject to further resource definition and technical studies.
  • Updated Sulista Mineral Resource targeted by end-2026: The resource estimate will incorporate the new results and further step-out and infill drilling.

NEXT STEPS

The priority work program at Sulista includes:

  • Complete the 2,000 m of follow-up drilling at Sulista South.
  • Advance Stage 2 and Stage 3 of the +10,000 m diamond drilling program, targeting further high-grade discoveries along the remaining 4.5 km of untested southern corridor.
  • Complete a further 5,000 m of infill and step-out diamond drilling across Sulista East, targeting conversion of a substantial majority of the Mineral Resource to Indicated classification.
  • Updated JORC Mineral Resource Estimate for Sulista, targeted for the end of 2026.

CEO COMMENTARY

“The Sulista South discovery gives us a new high-grade mineralised system to delineate, while successful drilling just at Sulista East is extending known mineralisation and strengthening the geological model. With more than 4.5 km of the southern corridor still untested by diamond drilling, significant exploration opportunity remains ahead of us.

Our next objective is an updated Mineral Resource by the end of 2026. Alongside that work, we will assess how Sulista could underpin additional high-grade feed to our planned Camaçari processing hub and support long-term province-scale growth around shared infrastructure. That potential currently remains outside the published Scoping Study.”

— Bernardo da Veiga, CEO & Managing Director

A link to the complete announcement can be found: here

Contacts

Bernardo Da Veiga
Managing Director and CEO

investors@brazilianrareearths.com
www.brazilianrareearths.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8112026-18ef-4152-b203-19fad6453d93

SINGAPORE, Oct. 01, 2026 (GLOBE NEWSWIRE) — StoneX Group Inc. (“StoneX”; NASDAQ: SNEX) today announced the launch of its Singapore FX booking center and SG1 connectivity, marking a significant expansion of its foreign exchange capabilities in the Asia-Pacific region.

StoneX FX, the institutional FX division of StoneX, offers OTC trading solutions for institutional and corporate hedging. Its award-winning FX market access model enables clients to trade spot, forwards, NDFs, swaps, and options with efficiency and transparency.

The new booking center enables StoneX FX to provide local pricing and execution from Singapore, improving response times, enhancing regional expertise, and aligning client support with APAC market hours. The development builds on the firm’s established global FX infrastructure, including its NY4 and LD4 hubs, and reflects continued investment in delivering global market access with localized service.

By bringing pricing, support, and decision-making closer to clients in Asia, StoneX aims to improve execution quality and operational efficiency for both institutional and corporate clients. The Singapore booking center is designed to support a broad range of trading and hedging needs, from low-touch, high-frequency institutional flows to high-touch corporate treasury operations.

The launch also strengthens StoneX FX’s offering for deliverable FX in Asia, helping clients better manage settlement timelines, regional currency workflows, and intraday liquidity requirements. Local booking reduces reliance on overnight handovers, allowing for faster execution adjustments, improved cash flow management, and more precise risk controls.

In parallel with the SG1 launch, StoneX FX has expanded its APAC currency coverage, adding seven new CNH pairs and enhancing liquidity across key regional currencies including JPY, SGD, HKD, KRW, TWD, INR, IDR, PHP, THB, and AED. This broader coverage supports clients trading, hedging, and managing exposure across Asian markets.

Gerard Melia, Global Head of FX Sales, StoneX, commented:
“The launch of our Singapore booking center is a meaningful step in strengthening our FX offering in Asia-Pacific. By aligning pricing and execution with regional market hours, we are able to deliver faster, more relevant support and help our clients navigate increasingly dynamic FX markets with greater precision.”

Greg Kallinikos, CEO of APAC, StoneX, stated:
“Singapore is a key global FX hub, and establishing SG1 connectivity for our new, local booking center allows us to bring our liquidity, technology, and expertise closer to clients in the region. This enhances not only execution quality, but also the overall client experience across trading, hedging, and settlement.”

About StoneX:
StoneX Group Inc., through its subsidiaries, operates a global financial services network that connects companies, organisations, traders, and investors to the global market ecosystem through a unique blend of digital platforms, end-to-end clearing and execution services, high-touch service, and deep expertise. The company strives to be its clients’ trusted partner, providing its network, products, and services to help them pursue business opportunities, manage market risks, make informed investment decisions, and improve their business performance. 

A Fortune 50 company headquartered in New York City and listed on the Nasdaq Global Select Market (NASDAQ: SNEX), StoneX Group Inc. and its more than 5,400+ employees serve over 80,000+ commercial, institutional, and payments clients, as well as more than 260,000 retail accounts, across more than 80 offices on six continents. Further information is available at www.stonex.com/en/ 

Media inquiries:
media@stonex.com

SNEX-G

  • Pre-certified SEooC Platform Available – Supporting reduction of customer integration effort, development time, and assessment burden
  • Fault Handling Mechanism Implemented – Minimizing Video CODEC IP malfunction risks in autonomous driving vision systems
  • Low Hardware Overhead Architecture Proven – Supporting high levels of functional safety without sacrificing chip area or power efficiency
  • Advanced Codec Lineup Ready for Automotive Integration – Successfully porting ASIL-B safety to legacy H.264/AVC, H.265/HEVC, AV1 by AOM, and infotainment-dominant VP9 codecs
  • Rigorous Safety Assessment Successfully Concluded – Strengthening access to the global automotive supply chain through certification by DNV

SEOUL, South Korea, Sept. 30, 2026 (GLOBE NEWSWIRE) — Chips&Media (CEO Steve Kim, KOSDAQ: 094360), a leading global provider of multimedia intellectual property (IP), announced today that its next-generation video codec hardware IP, ‘WAVE6331X FuSa (Functional Safety),’ has officially achieved the ISO 26262 ASIL-B certification from the independent third-party global certification body, DNV.

This milestone is the direct result of more than two years of intensive R&D investment, driven by predicting the explosive demand in the future automotive market. With this certification, Chips&Media secures a unique competitive edge to lead the high-value automotive semiconductor sector, including Advanced Driver Assistance Systems (ADAS) and In-Vehicle Infotainment (IVI), moving beyond its established success in the mobile and consumer compute markets.

Fault Handling Mechanism: Fault Detection and Reaction to Support Functional Safety
As modern vehicles transform into autonomous driving platforms, the functional safety of video Codecs that process camera streams has become increasingly important for supporting safe vehicle operation. When internal hardware faults or data corruption occur due to harsh automotive environments, Chips&Media’s WAVE6331X FuSa is designed to detect relevant anomalies and support transition of the system into a safe state within the defined fault response time. This fault handling capability helps mitigate the risk of potential autonomous driving malfunctions caused by frozen or corrupted video frames.

Architectural Efficiency: Supporting ASIL-B Safety Objectives with Minimal Hardware Overhead
In semiconductor designs for functional safety, achieving a defined ASIL target often requires additional safety mechanisms, which may increase chip area and power consumption. Chips&Media’s low-power architecture is designed to balance functional safety requirements with area and power efficiency. By integrating safety mechanisms such as real-time CRC protection and instruction flow monitoring into the IP architecture, WAVE6331X FuSa is designed to detect relevant faults and support achievement of the ASIL-B safety target under the defined assumptions of use, while minimizing hardware area and power penalties.

Advanced Multimedia Synergy: Porting Automotive Safety to AV1 and VP9
While automotive video solutions have traditionally been limited to established codec standards due to certification challenges, Chips&Media has expanded the applicability of ISO 26262-based functional safety development to AVC/HEVC, AV1, and VP9 codec IPs. This provides automotive semiconductor manufacturers with greater flexibility to integrate advanced video technologies while supporting functional safety requirements for connected vehicle applications.
Chips&Media is also preparing to apply the same functional safety technology framework to emerging video standards such as AV2 and VVC (Versatile Video Coding), paving the way for future commercial deployment.

Commitment: “We Finished the Hard Work; Customers Just Build the Chip”
This SEooC certification is expected to help automotive System-on-Chip (SoC) developers reduce integration effort and support development of their chip-level functional safety. Normally, tier-1 suppliers and chip makers have to spend months of labor and massive budgets to verify every internal block for final OEM submission. Chips&Media provides a certified SEooC package, including a Safety Manual, to support customers’ integration, verification, and safety assessment activities at the SoC level.

“Achieving the ISO 26262 ASIL-B certification proves that Chips&Media’s functional safety design capabilities are world-class, marking our official evolution from a multimedia IP provider into a global automotive safety leader,” stated Steve Kim, CEO of Chips&Media. “Chips&Media’s video codec IP is adopted by three of the world’s top five automotive chipmakers. Our comprehensive safety manual and guidelines will help to reduce development risks and effort for our global partner network. Moving forward, we will expand aggressively beyond being a traditional multimedia vendor to become an essential, trusted technology partner leading the future autonomous driving and mobility ecosystem.”

About Chips&Media Inc.

Chips&Media is a multimedia IP leader offering HW video codec IP, image processing NPU, lossless/lossy frame buffer compression IP and more. Since 2003, Chips&Media has exclusively focused on the HW video codec IP industry. It has powered over 3,000,000,000 units in the market, adopted by more than 150 semiconductor companies. Chips&Media’s video codec IP supports all major and legacy formats from 1080p up to 8K 120fps, including HEVC/H.265, AVC/H.264, AV1, AV2, VP9, APV, VVC/H.266, JPEG and others. The recent introduction of our image processing NPU IP is transforming Chips&Media into a premium multimedia IP provider. It is a custom NPU designed to work for imaging applications at high-quality and high-resolution in edge devices. For more information, please visit our website at www.chipsnmedia.com

CONTACT: Eniel Lee
eniel.lee@chipsnmedia.com

  • Pre-certified SEooC Platform Available – Supporting reduction of customer integration effort, development time, and assessment burden
  • Fault Handling Mechanism Implemented – Minimizing Video CODEC IP malfunction risks in autonomous driving vision systems
  • Low Hardware Overhead Architecture Proven – Supporting high levels of functional safety without sacrificing chip area or power efficiency
  • Advanced Codec Lineup Ready for Automotive Integration – Successfully porting ASIL-B safety to legacy H.264/AVC, H.265/HEVC, AV1 by AOM, and infotainment-dominant VP9 codecs
  • Rigorous Safety Assessment Successfully Concluded – Strengthening access to the global automotive supply chain through certification by DNV

SEOUL, South Korea, Sept. 30, 2026 (GLOBE NEWSWIRE) — Chips&Media (CEO Steve Kim, KOSDAQ: 094360), a leading global provider of multimedia intellectual property (IP), announced today that its next-generation video codec hardware IP, ‘WAVE6331X FuSa (Functional Safety),’ has officially achieved the ISO 26262 ASIL-B certification from the independent third-party global certification body, DNV.

This milestone is the direct result of more than two years of intensive R&D investment, driven by predicting the explosive demand in the future automotive market. With this certification, Chips&Media secures a unique competitive edge to lead the high-value automotive semiconductor sector, including Advanced Driver Assistance Systems (ADAS) and In-Vehicle Infotainment (IVI), moving beyond its established success in the mobile and consumer compute markets.

Fault Handling Mechanism: Fault Detection and Reaction to Support Functional Safety
As modern vehicles transform into autonomous driving platforms, the functional safety of video Codecs that process camera streams has become increasingly important for supporting safe vehicle operation. When internal hardware faults or data corruption occur due to harsh automotive environments, Chips&Media’s WAVE6331X FuSa is designed to detect relevant anomalies and support transition of the system into a safe state within the defined fault response time. This fault handling capability helps mitigate the risk of potential autonomous driving malfunctions caused by frozen or corrupted video frames.

Architectural Efficiency: Supporting ASIL-B Safety Objectives with Minimal Hardware Overhead
In semiconductor designs for functional safety, achieving a defined ASIL target often requires additional safety mechanisms, which may increase chip area and power consumption. Chips&Media’s low-power architecture is designed to balance functional safety requirements with area and power efficiency. By integrating safety mechanisms such as real-time CRC protection and instruction flow monitoring into the IP architecture, WAVE6331X FuSa is designed to detect relevant faults and support achievement of the ASIL-B safety target under the defined assumptions of use, while minimizing hardware area and power penalties.

Advanced Multimedia Synergy: Porting Automotive Safety to AV1 and VP9
While automotive video solutions have traditionally been limited to established codec standards due to certification challenges, Chips&Media has expanded the applicability of ISO 26262-based functional safety development to AVC/HEVC, AV1, and VP9 codec IPs. This provides automotive semiconductor manufacturers with greater flexibility to integrate advanced video technologies while supporting functional safety requirements for connected vehicle applications.
Chips&Media is also preparing to apply the same functional safety technology framework to emerging video standards such as AV2 and VVC (Versatile Video Coding), paving the way for future commercial deployment.

Commitment: “We Finished the Hard Work; Customers Just Build the Chip”
This SEooC certification is expected to help automotive System-on-Chip (SoC) developers reduce integration effort and support development of their chip-level functional safety. Normally, tier-1 suppliers and chip makers have to spend months of labor and massive budgets to verify every internal block for final OEM submission. Chips&Media provides a certified SEooC package, including a Safety Manual, to support customers’ integration, verification, and safety assessment activities at the SoC level.

“Achieving the ISO 26262 ASIL-B certification proves that Chips&Media’s functional safety design capabilities are world-class, marking our official evolution from a multimedia IP provider into a global automotive safety leader,” stated Steve Kim, CEO of Chips&Media. “Chips&Media’s video codec IP is adopted by three of the world’s top five automotive chipmakers. Our comprehensive safety manual and guidelines will help to reduce development risks and effort for our global partner network. Moving forward, we will expand aggressively beyond being a traditional multimedia vendor to become an essential, trusted technology partner leading the future autonomous driving and mobility ecosystem.”

About Chips&Media Inc.

Chips&Media is a multimedia IP leader offering HW video codec IP, image processing NPU, lossless/lossy frame buffer compression IP and more. Since 2003, Chips&Media has exclusively focused on the HW video codec IP industry. It has powered over 3,000,000,000 units in the market, adopted by more than 150 semiconductor companies. Chips&Media’s video codec IP supports all major and legacy formats from 1080p up to 8K 120fps, including HEVC/H.265, AVC/H.264, AV1, AV2, VP9, APV, VVC/H.266, JPEG and others. The recent introduction of our image processing NPU IP is transforming Chips&Media into a premium multimedia IP provider. It is a custom NPU designed to work for imaging applications at high-quality and high-resolution in edge devices. For more information, please visit our website at www.chipsnmedia.com

CONTACT: Eniel Lee
eniel.lee@chipsnmedia.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.